Clinical-stage pharmaceutical company Plus Therapeutics (NASDAQ: PSTV) is still struggling to make significant revenue while having almost fatalistic EPS (12 months) that chase long term investors away.
On August 3 top management informed the stakeholders about the announcement of the second quarter of 2020 financial results. If any positive change arises there is a big likelihood that PSTV will soar higher.
3 days left to wait and more investors may gather around the penny PSTV by increasing daily volume. For now, short term traders are buying its shares with hope of getting speculative margin, maybe at least 50%. However, soon bigger corporations may turn their sight on PSTV with the intention of acquiring the entire company.
Finance and Entertainment Reporter
Richard is a bottle of wine – the older the sweeter. He has already found the sweetest hobby in writing entertainment and finance news for Own Snap. Readers get the updated posts regularly from him searching for real-time news.